Table 3. The analytic results and clinical characteristics of hips converting to THA.
| Index | Number of hips | Hips converting to THA | Survival rate at 3-year (SE) | Survival rate at 5-year (SE) | P value (Log-rank test) |
|---|---|---|---|---|---|
| n | 104 | 49 | 70.8% (4.5%) | 47.5% (5.5%) | |
| Gender (M/F) | 77/27 | 34/15 | 76.4% (4.9%)/54.9% (6.2%) | 48.9% (6.6%)/42.2% (9.8%) | 0.244 |
| BMI ≧ 25 kg/m2 (Yes/No) | 49/55 | 22/27 | 71.2% (6.5%)/70.4% (6.2%) | 49.5% (8.0%)/45.1% (7.3%) | 0.515 |
| Invasive hip (uni/bi) | 76/28 | 42/7 | 68.5% (4.9%)/85.7% (9.4%) | 48.2% (5.9%)/44.5% (14.3%) | 0.802 |
| bone marrow edema (Yes/No) | 54/50 | 24/25 | 72.2% (6.1%)/69.6% (6.6%) | 54.8% (6.9%)/35.8% (8.9%) | 0.332 |
| preoperative HHS ≧ 80 scores (Yes/No) | 48/56 | 18/31 | 80.6% (5.8%)/62.4% (6.5%) | 52.9% (8.9%)/42.7% (6.9%) | 0.078 |
| etiology | 0.589 | ||||
| corticosteroids | 50 | 26 | 67.8% (6.6%) | 45.5% (7.3%) | |
| alcohol | 40 | 17 | 79.7% (6.4%) | 46.3% (9.7%) | |
| idiopathic | 14 | 6 | 57.1% (13.2%) | 57.1% (13.2%) | |
| Age (years) | 0.034 | ||||
| 35 | 72 | 39 | 67.8% (5.5%) | 38.1% (6.8%) | |
| ≤35 | 32 | 10 | 77.7% (7.4%) | 66.0% (8.9%) | |
| ARCO stage | 0.001 | ||||
| Stage II | 42 | 11 | 85.6% (5.5%) | 65.4% (9.3%) | |
| Stage III | 62 | 38 | 60.7% (6.3%) | 36.0% (6.4%) | |
| CJFH type | 0.001 | ||||
| L1 | 13 | 0 | |||
| L2 | 53 | 24 | 73.5% (6.1%) | 49.6% (7.6%) | |
| L3 | 38 | 25 | 57.9% (8.0%) | 28.8% (8.1%) |